AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Arbutus Biopharma Corporation Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S6RSK0
4.20▼ 0.01 (-0.24%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
4.21
Day's Range
4.12 – 4.22
52-Week Range
3.50 – 5.45
Volume
2.0M
Avg Volume
6.4M
Share Statistics
Shares Outstanding
Employees
19
Exchange
XNAS
Listed
2007-07-26
Share count as of August 10, 2026

Arbutus Biopharma Corporation Common Stock (ABUS) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Arbutus Biopharma Corporation Common Stock (ABUS)
What is Arbutus Biopharma Corporation Common Stock's Market Cap?
Arbutus Biopharma Corporation Common Stock's Market Cap is $831.0M, based on as-reported figures from SEC (XBRL) filings.
What is Arbutus Biopharma Corporation Common Stock's Enterprise Value?
Arbutus Biopharma Corporation Common Stock's Enterprise Value is $811.8M, based on as-reported figures from SEC (XBRL) filings.
What is Arbutus Biopharma Corporation Common Stock's Trailing P/E?
Arbutus Biopharma Corporation Common Stock's Trailing P/E is 5.4×, based on as-reported figures from SEC (XBRL) filings.
What is Arbutus Biopharma Corporation Common Stock's Price / Sales?
Arbutus Biopharma Corporation Common Stock's Price / Sales is 4.6×, based on as-reported figures from SEC (XBRL) filings.
What is Arbutus Biopharma Corporation Common Stock's EV / Revenue?
Arbutus Biopharma Corporation Common Stock's EV / Revenue is 4.5×, based on as-reported figures from SEC (XBRL) filings.
What is Arbutus Biopharma Corporation Common Stock's EV / EBITDA?
Arbutus Biopharma Corporation Common Stock's EV / EBITDA is 5.4×, based on as-reported figures from SEC (XBRL) filings.
What is Arbutus Biopharma Corporation Common Stock's Revenue (TTM)?
Arbutus Biopharma Corporation Common Stock's Revenue (TTM) is $181.7M, based on as-reported figures from SEC (XBRL) filings.
What is Arbutus Biopharma Corporation Common Stock's Net Income (TTM)?
Arbutus Biopharma Corporation Common Stock's Net Income (TTM) is $153.1M, based on as-reported figures from SEC (XBRL) filings.
What is Arbutus Biopharma Corporation Common Stock's EBITDA?
Arbutus Biopharma Corporation Common Stock's EBITDA is $149.4M, based on as-reported figures from SEC (XBRL) filings.
What is Arbutus Biopharma Corporation Common Stock's Diluted EPS (TTM)?
Arbutus Biopharma Corporation Common Stock's Diluted EPS (TTM) is 0.77, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ABUSAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
Revenues—
YoY growth-90.6%+10054.5%—-60.5%
Operating expenses
Research and development
General and administrative
Change in fair value of contingent consideration
Restructuring costs
Total operating expenses
% of revenue688.2%5.7%—1736.9%
(Loss) income from operations
% of revenue-588.2%94.3%—-1636.9%
Interest income
Interest expense
Foreign exchange (loss) gain
Total other income
Net (loss) income
% of revenue-507.2%94.7%—-1463.5%
Net (loss) income per common share
Basic (in USD per share)—
Diluted (in USD per share)—
Comprehensive (loss) income
Unrealized loss on available-for-sale securities——
Comprehensive (loss) income